Skip to main content

Table 3 Safety, tolerability, and adverse effects of melatonin and placebo

From: Melatonin supplementation to treat the metabolic syndrome: a randomized controlled trial

Parameter Melatonin Placebo Fisher’s P value
N 39 39  
Nausea, patients reporting "Yes" (N, %)    
 Pre 2/39 (5.1%) 3/38 (7.9%) 0.675
 Post 3/38 (7.9%) 4/36 (11.1%) 0.707
Dizziness, patients reporting "Yes" (N, %)    
 Pre 8/39 (20.5%) 8/38 (21.1%) 1.00
 Post 8/38 (21.1%) 10/35 (28.6%) 0.588
Fatigue, patients reporting "Yes" (N, %)    
 Pre 20/39 (51.3%) 15/38 (39.5%) 0.363
 Post 23/38 (60.5%) 19/36 (52.8%) 0.639
Drowsiness, patients reporting "Yes" (N, %)    
 Pre 22/39 (56.4%) 18/37 (48.6%) 0.646
 Post 22/37 (59.5%) 17/36 (47.2%) 0.352
Early morning awakening or sleep disturbances, patients reporting "Yes" (N, %)    
 Pre 19/39 (48.7%) 22/37 (59.5%) 0.368
 Post 22/37 (59.5%) 23/36 (63.9%) 0.811